Rare diseases
Investigational molecules
Locations
333 Lakeside Drive, 94404-1147, United States
Research activity centers on oral maintenance and switching regimens for virologically suppressed people with HIV-1 infection, treatment-naive populations, and prevention strategies for individuals at risk of acquisition. The portfolio also includes pediatric and adolescent studies, reflecting interest across age groups and clinical settings.
Key areas include lenacapavir, islatravir, bictegravir, emtricitabine, tenofovir alafenamide, and combination regimens designed to support long-term HIV management.
Gilead Sciences Inc. runs clinical trials in conditions such as HIV infection, Non-small cell lung cancer, Triple negative breast cancer, Hepatitis D, among others.
Clinical trials run by this sponsor – those enrolling participants first.
FranceFranceFrance
Bulgaria
BelgiumFrance
AustriaBelgiumBelgium
ItalyFranceBelgiumIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
